Clinical research · November 20, 2026 · JNJ

JNJ Reports Detailed Tremfya STAR Trial Results

Reported company results

Johnson & Johnson’s November 20 release provides detailed Phase 4 STAR results for Tremfya in adults with active psoriatic arthritis and MRI-confirmed axial involvement who had not previously received biologic therapy. The company reports 411 participants in the randomized, double-blind, placebo-controlled study.

At Week 24, the patient-reported BASDAI disease-activity score improved by 3.3 points with four-week dosing and 2.9 points with eight-week dosing, versus 2.1 points with placebo. The release also reports improved MRI-assessed inflammation.

Two qualifications matter: the company states that four-week dosing is not approved in the United States, and that the eight-week group’s improvement on the HAQ-DI disability measure did not reach statistical significance.

Analysis

For JNJ readers, detailed endpoint results help put the headline in context. The selected study population, individual outcome measures and dosing schedules limit broad conclusions about all patients or treatment regimens.

This company report does not establish superiority over another active drug, and it is not a new regulatory approval announcement. Clinical findings also do not by themselves quantify future sales or earnings. We make no treatment recommendation, stock-price forecast or buy or sell recommendation.

Related reading

Browse the market-report index or return to the clock dashboard.